Cerebral ischemic events and anti-cancer therapy;Accidents ischémiques cérébraux et chimiothérapie anti-cancéreuse

Revue Neurologique

Volumn 159, Issue 4, 2003, Pages 371-380

  El Amrani, M ^a   Aidi, S ^a   Amarenco, P ^b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ASPARAGINASE; AZATHIOPRINE; BLEOMYCIN; BLOOD CLOTTING FACTOR; BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HOMOHARRINGTONINE; METHOTREXATE; MITOMYCIN; PREDNISONE; TIOGUANINE; URETHAN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APLASIA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; BUDD CHIARI SYNDROME; CANCER CHEMOTHERAPY; CARCINOMATOUS MENINGITIS; CEREBROVASCULAR ACCIDENT; ERYTHEMA; ESOPHAGUS CANCER; HEART INFARCTION; HUMAN; HYPOTENSION; LARYNX CANCER; LIVER VEIN OBSTRUCTION; LUNG CANCER; NAUSEA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OCCLUSIVE CEREBROVASCULAR DISEASE; OROPHARYNX CANCER; OSTEOSARCOMA; OVARY TUMOR; PHARYNX TUMOR; PULMONARY VEIN OBSTRUCTION; RAYNAUD PHENOMENON; REVIEW; SARCOMA; STROKE; TERATOMA; TESTIS TUMOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ASPARAGINASE; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CHILD; CHILD, PRESCHOOL; CISPLATIN; DISEASE SUSCEPTIBILITY; FEMALE; FLUOROURACIL; GROWTH INHIBITORS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASMS;

EID: 0037960145     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. ALMENAREZ JA, MARTIN JMENEZ M, DIAZ RUBIO E, GURRERO SOLA A. (1985). Infarto cerebral tras la administracion de cisplatino. Neoplasia, 5: 226-227.
2. AL TWEIGERI T, MAGLIOCCO AM, DECOTEAU JF. (1999). Cortical blindness as a manifestation of hypomagnesemia secondary to cisplatin therapy: case report and review of literature. Gynecol Oncol, 72: 120-122.
3. ALLEN JC, ROSEN GR. (1978). Transient cerebral dysfonction following chimiotherapy for osteogenic sarcoma. Ann Neurol, 3: 441-444.
4. ATKINS JN, MUSS HB, CASE D, et al. (1991). High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol, 14: 526-529.
5. BACHAUD JM, DAVID JM, SHUBINSKI RE, et al. (1993). Predictive factors of a complete response to an advers effect of a CDDP-5FU combination as primary therapy for head and neck squamous carcinomas. J Laryngol Otol, 107: 924-930.
6. BAUDIN B. (1995). Toxicité endothéliale des chimiothérapies anti-cancéreuses. Sang Thromb Vaiss, 7: 175-183.
7. BERMAN IJ, MANN MP. (1980). Seizures and transient cortical blindness associated with cis-platinium (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer, 45: 764-766.
8. BEUZEBOC P, LIVARTOWSKI A, DIERICK A, PARAISO D, POUILLART P. (1995). Continuous infusion cisplatin and 5-fluorouracil with bolus vinorebline in the treatment of advanced nonsmall cell carcinoma of the lung. J Infus Chemother, 5: 193-194.
9. BONI C, MORETTI G, SAVOLDI L, et al. (1996). Neoadjuvant chemotherapy with continuous infusion of cisplatin and fluorouracil in stage II-W, Mo squamous cell carcinoma of the head an neck. Tumori, 82: 567-572.
10. BORGNA-PIGNATTI C, BATTIDTI L, MARRADI P, BALTER R, CAUDANA. (1992). Transient neurologic disturbances in a child treated with moderate-dose méthotrexate. Br J haematol, 81: 448.
11. CANTWELL BMJ, MANNIX KA, ROBERT JT, et al. (1988). Thromboembolic events after cisplatin-based combination chemotherapy for germ cell malignacy. Lancet, II: 1086-1087.
12. CLARK R, DALY L, ROBINSON K, et al. (1991). Hyperhomocysteinemia: an independent risk factor for vascular disease. N Eng J Med, 324: 1149-1150.
13. CLAVEL M, SMÉONE P, GRIVET B. (1988). Toxicité cardiaque du 5-Fluorouracile. Revue de la littérature, cinq nouveaux cas. Press Méd, 17: 1657-1678.
14. CLAVELL LA, GELBER RD, COHEN HJ, et al. (1986). Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med, 315: 657-663.
15. CONARD J, CAZENAV B, MAURY J, HORELLOU MH, SAMAMA M. (1980). L-asparaginase, antithrombine III and thrombosis. Lancet, 1: 1091.
16. CONARD J, HORELLOU MH, DREDEN PV, POTEVIN F, ZITTOUN R, SAMAMA M. (1985). Decrease in proteine C in L-asparaginase treated patients. Br J Haematol, 59: 725.
17. CRISPINO O, PIZZACARO G, SOLERO CL, RODARI A, MONFARDINI S. (1984). Transient left homonymous hemianopsia during treatment of testicular carcinoma with cisplatinium, vinblastine, a bleomycin. Chemioterapia, 3: 337-339.
18. DELATTRE JY, POISSON M. (1990). Complications neurologiques de la radiothérapie cérébrale: apport des études expérimentales. Bull Cancer, 77: 715-724.
19. DIAMOND SB, RUDOLPH SH, LUBICZ SS, DEPPE G, COHEN CJ. (1982). Cerebral blindness in association with cis-platinium chemotherapy for advanced carcinoma of the fallopian tube. Obstet Gynecol, 59:84S-86S.
20. DOLL DC, LIST AF, GRECO FA, HAINSWORTH JD, HANDE KR, JOHNSON DH. (1986). Acute vascular ischemic events after cisplatinbased combination chemotherapy for germ-call tumors of the testis. Ann Inten Med, 105: 48-51.
21. DOLL DC, RINGENBERG QS, YARBO JW. (1986). Vascular toxicity associated with antineoplasic agents. J Clin Oncol, 4: 1405- 1417.
22. EL AMRANI M, HEINZLEF O, DEBROUCKER T, ROULLET E, BOUSSER MG, AMARENCO P. (1998). Brain infarction following 5-Fluorouracile and cisplatin therapy. Neurology, 51: 899-901.
23. ENEVOLDSON TP. (1989). Acute cerebral oedema induced by méthotrexate. BMJ, 299: 516.
24. FEINBERG WM, SWENSON MR. (1988). Cerebrovascular complications of L-Asperginase therapy. Neurology, 38: 127-133.
25. FOREMAN NK, MAHMOUD HH, LANGSTON J. (1992a). 99Tcm-HMPAO SPECT and magnetic resonance studies in L-asparaginase induced cerebrovascular accident. The British Journal of Radiology, 65:78-81.
26. FOREMAN NK, MAHMOUD HH, RIVERA GK, CRIST WM. (1992b). Recurrent cerebrovascular accident with L-asparaginase rechallenge. Medical and Pediatric Oncology, 20: 532-534.
27. GAMBLE GE, TYRRELL P. (1998). Acute stroke following cisplatin therapy. Clin Oncol, 10: 274-275.
28. GANDIA D, SPIELMANN M, KAC J, et al. (1992). Cerebrovascular accident associated with chemotherapy for oesophgeal carcinoma. Eu J Cancer, 28: 245.
29. GERL A, CLEMM C, SCHLEUNING M, WILMANNS W. (1993). Fatal cerebrovascular accident associated with chemotherapy for testicular cancer. Eur J Cancer, 29A: 1220-1221.
30. GERL A, CLEMM C, WILMANNS W. (1991). Acute cerebrovascular event after cisplatin-based chemotherapy for testicular cancer. Lancet, 338: 385-386.
31. GERL A. (1994). Vascular toxicity associated with chemotherapy for testicular cancer. Anticancer Drugs, 5: 607-614.
32. GITENBEEK JMM, VAN DEN BENT MJ, VECHT CJ. (1999). Cyclosporine neurotoxicity: a review. J Neurol, 246: 339-346.
33. GOLDHIRSCH A, JOSS R, MARKWALDER TM, STUDER H, BRUNNER K. (1983). Acute cerebrovascular accident after treatment with cisplatinium and methylprednisolone. Oncology, 40: 344-345.
34. GORMAN DJ, KEFFORD R, STUART-HARRIS AL. (1989). Focal encephalopathy after cisplatin therapy. Med J Aust, 150: 399-401.
35. GRADISHAR WJ, VOKES EE. (1990). 5-fluoro-uracil cardiotoxicity: a critical review. Annals of Oncology, 1: 409-414.
36. GRAUS F, ROGER L, POSNER J. (1985). Cerebrovascular complications in patients with cancer. Medecine, 64: 16-35.
37. GUÉRIN JM, MOFREDJ A, LEIBINGER F, EKHERIAN JM. (1998). Toxicité neurologique du méthotrexate avec artérite cérébrale. Un cas. Rev Neurol, 154: 700-702.
38. HANKEY GJ, EIKELBOOM JW. (1999). Homocysteine and vascular disease. Lancet, 354: 407-413.
39. HERAN F, DEFER G, BRUGIERES VP, BRENOT F, GASTON A, DEGOS JD. (1990). Cortical blindness during chemotherapy: clinical, CT, and MR correlations. J Comput Assist Tomogr, 14: 262-266.
40. HIGA GM, WISE TC, CROWELL EB. (1995). Severe disabling neurologic toxicity following cisplatin retreatment. Ann Pharmacother, 29: 134-137.
41. HURWITZ RL, MAHONEY DH, ARMSTRONG DL, BROWDER TM. (1988). Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol, 16: 216-219.
42. IÇLI F, KARAOGUZ H, DINÇOL D, DEMIRKAZIK A, GÜNEL N, KARAOGUZ R, ÜNER A. (1993). Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer, 72: 587-593.
43. ISHII H, OH H, ISHIZUKA N, MATSUURA Y, NAKAMURA H, ASAI T, YOSHIDA S. (1992). Cerebral infarction in a patient with acute lymphoblastic leukemia after fresh-Forzen plasma replacement during L-asparaginase therapy. American Journal Of Hematology, 41: 295-296.
44. JACKSON AM, ROSE BD, GRAFF LG, et al. (1984). Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med, 101: 41-44.
45. JERECZEK-FOSSA B, DE BRAUD F, GASPARETTO M, et al. (1998). Induction chemotherapy followed by simultaneous hyperfractionated radiochemotherapy in advanced head and neck cancer. A pilot study. Strahlenther Onkol, 174: 457-461.
46. KINGMA A, TAMMINGA RYJ, KAMPS WA. (1993). Cerebrovascular complications of L-asparaginase therapy in children with leukemia: Aphasia and others neuropsychological deficits. Pediatric Hematology and Oncology, 10: 303-309.
47. KOMATSUMOTO S, USHIODA T, NARA M. (1996). Multiple cerebral infaction after treatment with cisplatin. Rinsho Shinkeigaku, 36: 499-502.
48. KUCUK O, KWAAN HC, GUNNAR W, VAZQUEZ RM. (1985). Tromboembolic complications associated with L-asparaginase therapy. Cancer, 55: 702-706.
49. KUKLA LJ, MCGUIRE WP, LAD T, SALTIER M. (1982). Acute vascular episodes associated with therapy for carcinomas of aerodigestive tract with blomycin, vincristine, and cisplatin. Cancer Treat Rep, 66: 369-70.
50. LEDERMAN GS. (1982). Stroke due to treatment with L-asperginase in adult. N Engl J Med, 137: 1643.
51. LEVINE M, HIRSH J, GENT M, et al. (1994). Lancet, 343: 886-889.
52. LIAU CT, YANG TS, WANG CH, HSUEH S. (1996). Intra-abdominal desmoplastic small cell tumors: report of two cases. Anticancer Drugs, 7: 228-232.
53. LICCIARDELLO JT, MOAKE JL, RUDY CK, KARP DD, HONG WK. (1985). Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chimiotherapy. Oncology, 42: 296-300.
54. LIM HL, TEO CP, WONG K, KUEH YK. (1998). L-asparaginase induced intracranial hemorrhage in acute lymphoblastic leukemiȧ. Singapore Med J, 39: 76-78.
55. MARTINEZ DEL PRADO P, MEANA JA, CARRION JF. (1992). Acute cerebrovascular accident after treatment with cisplatin. Acta Oncol, 31: 593-595.
56. MOLLMAN JE. (1990). Cisplatin neurotoxicity. N Engl J Med, 322: 126-127.
57. NOMURA K, OHNO R, HAMGUCHI K, HATA T, HATANAKA H, MATSUYAMA H. (1995). Clinicopathological report of cisplatin encephalopathy. Rinsho Shinkeigaku, 35: 64-69.
58. OHNO T, MATSUDA I, FURUKAWA H, KANOH T. (1994). Recovery from rhumatoide vasculitis by low-dose méthotrexate, Internal Medecine, 33: 615-620.
59. OTT N, RAMSAY NKC, PRIEST JR, LIPTON M, PUI CH, STEINHERZ P, NESBIT ME. (1988). Sequelae of thrombotic or hemorrhagic complications following L-Asparaginase therapy for childhood lymphoblastic leukemia. Am J Pediatre Hematol Oncol, 10: 191-195.
60. PARKER RJ, RORKE LB, LANGE BJ, SIEGEL KR, EVANS AE. (1985). Cerebrovascular accidents in children with cancer. Pediatrics, 76: 194-201.
61. PHILIP PA, CARMICHAEL J, HARRIS AL. (1991). Convulsion and transient cortical blindness after cisplatin. BMJ, 302: 416.
62. PIHKO H, TYNI T, VIRKOLA K, VALNNE L, SAINIO K, HOVI L, SAARINEN UM. (1993). Transient ischemic cerebral lesion during induction chemotherapy for acute lymphoblastic leukemia. J Pediatr, 123: 718-724.
63. PIPPITT CH, MUSS HB, HOMESLEY HD, JOBSON VW. (1981). Cisplatin-associated cortical blindness. Gynecologic Oncology, 12: 253-255.
64. PRIEST JR, RAMSAY NKC, BENNETT AJ, KRIVIT W, EDSON JR. (1982). The effect of L-asparaginase on antithrombi, plasminogen and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr, 100: 990-995.
65. PRIEST JR, RAMSAY NKC, LATCHAW RE, et aL (1980). Thrombotic and hemorrhgic strockes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer, 46: 1548-1554.
66. PRINET JM, GALZIN M, DEMARQUAY JF, KUNKEL D. (1995). Dysfonction myocardique nodale lors d'un traitement par 5-Fluorouracile. Sem Hôp Paris, 71:636-638.
67. PRITCHARD KI, PATERSON AHG, PAUL NA, ZEE B, FINE S, PATER J, FOR THE NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP BREAST CANCER SITE GROUP. (1996). Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol, 14: 2731-2737.
68. PROVINCIO M, BONILLA F, LACASTA A. (1994). Cerebral infarction after cisplatin-based chemotherapy. Postgrad Med J, 70: 525-526.
69. PUI CH, CHESNEY CM, WEED J, JACKSON CW. (1985). Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. J Clin Oncol, 3:1266-1272.
70. PUMAR JM, ARROJO L, SEOANE C, GARCIA R, CASTINEIRA JA, VIDAL J. (1994). Magnetic resonance signal alteration of the brain in asymptomatic patients treated with-high dose cisplatin for ovarian carcinoma. Eur J Cancer, 30: 21.
71. QUINN CT, GRIENER JM, BOTTIGLIERI T, HYLAND K, FARROW A, KAMEN BA. (1997). Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive méthotrexate for the treatment of cancer. J Clin Oncol 15: 2800-2806.
72. RAU R, SCHLEUSSER B, HERBORN G, KARGER T. (1997). Longterm treatment of destructive rhumatoid arthritis with méthotrexate J Rheumatol, 24: 1881-1889.
73. ROTH BJ, GREIST A, KUBILIS PS, WILLIAMS SD, EINHORN LH. (1988). Cisplatin-based combination chemotherapy for disseminated germ-cell tumors: long-term follow-up. J Clin Oncol, 6:1239-1247.
74. SAMOUN M, POTOCKA AC, PILLIĖRE R, DELORME G, PRINSEAU J, BAGLIN A. (1991). Cardiotoxicité du 5-Fluorouracile. Deux observations. Press Méd, 20: 458-460.
75. SAMUELS BL, VOGELZANG NJ, KENNEDY BJ. (1987). Severe vascular toxicity associated with vinblastine, bleomycin and cisplatin chemotherapy. Cancer Chemother Pharmacol, 19: 253-256.
76. SAPHNER T, TORMEY DC, GRAY R. (1991). Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol, 9: 286-294.
77. SCHILSKY RL, ANDERSON T. (1979). Hypomagnesemia and renal magnesium wasing in patients receiving cisplatin. Ann Intem Med, 90:929-931.
78. SERRE I, DELATTRE JY, POISSON M. (1993). Accidents vasculaires cerébraux et cancers. Ann Med Int, 144: 406-418.
79. TAYLOR SM, MURTHY AK, GRIEM LK, et al. (1997). Concomitant cisplatin/5-FU infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results. HEAD NECK, 19: 684-691.
80. VAN GELDER T, GEURS Ph, KHO GS, DIPPEL DWJ, VECHT ChJ, SPLINTER TAW. (1993). Cortical blindness and seizures following cisplatin treatment: both of epileptic origin? Eur J Cancer, 29 A: 1497-1498.
81. VIKRAM B, CHADHA M, MALAMUD S, Yu L. (1994). Patterns of failure in carcinoma of the upper esophagus after alternating chemoradiotherapy. Am J Surg, 168: 423-424.
82. VOGELZANG NJ, TORKELSON JL, KENNEDY BJ. (1985). Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastin, and bleomycin. Cancer, 56: 2765-2770.
83. WALL JG, WEISS RB, NORTON L, PERLOFF M, RICE MA, KORZUN AH, WOOD WC. (1989). Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a cancer and leukemia group B study. Am J Med, 87: 501-504.
84. WATANABE I, SAKAI I, MATSUMOTO I. (1992). Superior sagittal sinus thrombosis following L-asparaginase therapy of acute lymphoblastic leukemia. Rinsho Ketsueki, 33: 343-348.
85. WHITE L, FISHMAN LS, SHORE NA. (1981). Strokes and neurotoxicity of L-asparaginase. J Pediatr, 99: 168.
86. WOIMANT F, MOULIGNIER, LECOZ P, HAGUENEAU M, PÉPIN B. (1988). Accidents ischémiques cérébraux et coagulations intravasculaire disséminée d'origine cancéreuse. Rev Neurol (Paris), 144: 120-124.
87. YAMADA K, YAMASHIRO S, ITOYAMA Y, GOTO S, UEMURA S, USHIO Y. (1993). Sinus thrombosis during CDDP and VP-16 (PE) therapy for suprasellar germ-cell tumor: case report. No Shinkei Geka, 21: 1025-1029.
88. YIM YS, MAHONEY DH, OSHMAN DG. (1991). Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer, 67: 2058-2061.
89. YOUNG DC, MITCHELL A, KESSLER J, CHRISTMAN JE. (1993). Cortical blindness and seizure possible related to cisplatin, vinblastine and bleomycin treatment of ovarian dysgerminoma. J Am Osteopath Assoc, 93: 502-504.